Elazzouzi Amy 4

What Happened

• Amy Elazzouzi, Senior Vice President, Finance at Aura Biosciences (AURA), sold 8,549 shares on February 17, 2026.
• The shares were sold in the open market at a weighted average price of $5.06, resulting in gross proceeds of approximately $43,258. This was a sale (not a purchase) and was executed to satisfy tax withholding on vested restricted stock units.

Key Details

• Transaction date: 2026-02-17. Transaction type: Sale (S).
• Price: weighted average $5.06; trades ranged from $5.04 to $5.31 (per filing footnote).
• Shares sold: 8,549; proceeds ≈ $43,258.
• Purpose: Automatic sale to cover tax withholding for RSU vesting (footnote F1). The Reporting Person did not exercise discretion over these sales.
• Footnote F2: multiple trades at prices within the stated range; issuer or SEC staff can request breakdown of quantities at each price.
• Shares owned after transaction: Not disclosed in this Form 4.
• Filing timeliness: Reported and filed on 2026-02-17 (no late filing noted).

Context

• These withholding sales are routine when restricted stock units vest and do not necessarily signal the insider's view of the stock. They are different from voluntary sales or purchases that might reflect investment sentiment.
• For retail investors, purchases generally carry more informational weight than routine withholding sales; treat this transaction as administrative rather than an active vote of confidence or concern.